Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 90 yuan, compared to the current price of 68.30 yuan [3][6]. Core Insights - The company plans to acquire 100% equity of Yijie Medical for 335 million yuan, with 301 million yuan in shares and 34 million yuan in cash. The acquisition is progressing steadily [2][6]. - The company is expected to achieve significant revenue growth, with projected total revenue of 278 million yuan in 2024, increasing to 635 million yuan by 2027, representing a compound annual growth rate (CAGR) of approximately 30.9% [2][7]. - The net profit attributable to the parent company is forecasted to grow from 79 million yuan in 2024 to 221 million yuan in 2027, with a CAGR of 40.0% [2][7]. - The acquisition of Yijie Medical is anticipated to enhance the company's integrated solutions in neurosurgery and interventional fields, leveraging channel resources and expanding its technology applications [6][7]. - The controlling shareholder's stake is expected to increase from 32.97% to 37.88% post-acquisition, enhancing control over the company [6][7]. Financial Projections - Total revenue projections for 2024A, 2025E, 2026E, and 2027E are 278 million, 372 million, 485 million, and 635 million yuan, respectively, with year-on-year growth rates of 20.6%, 33.8%, 30.3%, and 30.9% [2][7]. - The net profit attributable to the parent company is projected to be 79 million, 113 million, 158 million, and 221 million yuan for the same years, with growth rates of 92.9%, 43.5%, 39.3%, and 40.0% [2][7]. - Earnings per share (EPS) are expected to rise from 1.18 yuan in 2024 to 3.31 yuan in 2027, with corresponding price-to-earnings (P/E) ratios decreasing from 58 to 21 [2][7].
迈普医学（301033）：重大事项点评：拟以3.35亿元收购易介医疗，收购稳步推进中